Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $21.39 billion. The enterprise value is $28.69 billion.
Important Dates
The next confirmed earnings date is Wednesday, November 5, 2025, before market open.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | Nov 14, 2025 |
Share Statistics
Royalty Pharma has 583.17 million shares outstanding. The number of shares has decreased by -2.95% in one year.
| Current Share Class | 432.29M |
| Shares Outstanding | 583.17M |
| Shares Change (YoY) | -2.95% |
| Shares Change (QoQ) | -2.73% |
| Owned by Insiders (%) | 11.56% |
| Owned by Institutions (%) | 80.81% |
| Float | 379.85M |
Valuation Ratios
The trailing PE ratio is 15.77 and the forward PE ratio is 7.65. Royalty Pharma's PEG ratio is 0.95.
| PE Ratio | 15.77 |
| Forward PE | 7.65 |
| PS Ratio | 6.92 |
| Forward PS | 6.77 |
| PB Ratio | 2.48 |
| P/TBV Ratio | 3.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 8.86 |
| PEG Ratio | 0.95 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 28.11 |
| EV / Sales | 12.45 |
| EV / EBITDA | n/a |
| EV / EBIT | 15.35 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.84.
| Current Ratio | 1.26 |
| Quick Ratio | 1.26 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 7.02 |
Financial Efficiency
Return on equity (ROE) is 17.29% and return on invested capital (ROIC) is 6.70%.
| Return on Equity (ROE) | 17.29% |
| Return on Assets (ROA) | 6.49% |
| Return on Invested Capital (ROIC) | 6.70% |
| Return on Capital Employed (ROCE) | 10.92% |
| Revenue Per Employee | $23.29M |
| Profits Per Employee | $10.31M |
| Employee Count | 99 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.52% in the last 52 weeks. The beta is 0.59, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | +34.52% |
| 50-Day Moving Average | 36.17 |
| 200-Day Moving Average | 34.25 |
| Relative Strength Index (RSI) | 52.38 |
| Average Volume (20 Days) | 2,211,394 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.31 billion and earned $1.02 billion in profits. Earnings per share was $2.32.
| Revenue | 2.31B |
| Gross Profit | 2.70B |
| Operating Income | 1.87B |
| Pretax Income | 1.66B |
| Net Income | 1.02B |
| EBITDA | n/a |
| EBIT | 1.87B |
| Earnings Per Share (EPS) | $2.32 |
Full Income StatementBalance Sheet
The company has $645.11 million in cash and $8.02 billion in debt, giving a net cash position of -$7.38 billion or -$12.65 per share.
| Cash & Cash Equivalents | 645.11M |
| Total Debt | 8.02B |
| Net Cash | -7.38B |
| Net Cash Per Share | -$12.65 |
| Equity (Book Value) | 9.50B |
| Book Value Per Share | 14.68 |
| Working Capital | 313.72M |
Full Balance SheetMargins
Gross margin is 117.12%, with operating and profit margins of 81.09% and 44.28%.
| Gross Margin | 117.12% |
| Operating Margin | 81.09% |
| Pretax Margin | 72.22% |
| Profit Margin | 44.28% |
| EBITDA Margin | n/a |
| EBIT Margin | 81.09% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $0.88, which amounts to a dividend yield of 2.40%.
| Dividend Per Share | $0.88 |
| Dividend Yield | 2.40% |
| Dividend Growth (YoY) | 4.76% |
| Years of Dividend Growth | 5 |
| Payout Ratio | 37.86% |
| Buyback Yield | 2.95% |
| Shareholder Yield | 5.36% |
| Earnings Yield | 4.79% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for Royalty Pharma is $46.00, which is 25.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.00 |
| Price Target Difference | 25.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 14.96% |
| EPS Growth Forecast (5Y) | 32.20% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.54 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.54 |
| Piotroski F-Score | 6 |
